[유상증자 모니터] '최대주주 교체' 세니젠, 경영 정상화 이룰까

Senigene's major shareholder transition and strategic capital raise mark a critical restructuring in the diagnostics sector, enabling the company to expand beyond food safety into genetic testing and drug development under new investor backing. The move exemplifies how struggling biotech companies seek market relevance through strategic investor partnerships rather than organic growth recovery. Success hinges on whether the company can translate financial infusion into operational improvements and profitability gains amid ongoing accounting concerns and historical losses.